AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04010630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Description: Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion.
Study NCT04608006 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine-fentanyl
Description: Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
Study NCT01464827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets
Study NCT01464827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
Study NCT02228070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: strabismus video goggles
Study NCT02626832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural
Description: All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
Study NCT01464827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules
Study NCT02953847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
Study NCT02953847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Study NCT00661466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge
Study NCT02804087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
Study NCT02804087 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Implantation
Description: Sham Implantation
Study NCT03513406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is indicated for the reversal of neuromuscular blockade.
Study NCT03513406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is indicated for the reversal of neuromuscular blockade.
Study NCT03513406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
Study NCT04857203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
Study NCT05028426 — intervention group
Intervention type: PROCEDURE
Intervention: Enhanced recovery program
Description: Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
Study NCT00677235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
Study NCT00677235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Treatment of stenoses with PTA only
Study NCT00122642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol-lock
Description: The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
Study NCT00122642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-lock
Description: The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
Study NCT00624481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20ug subcutaneous injection daily for 24 weeks
Study NCT00624481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Nasal Spray
Description: teriparatide intranasally daily for 24 weeks
Study NCT02158117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal naloxone
Description: one puff in one nostril with the subject is lying down
Study NCT00264420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
Study NCT00509834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLF1-11
Description: The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10
Study NCT00509834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLF1-11
Description: 0.5mg hLF1-11 iv per day for 14 consecutive days
Study NCT00509834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03258216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: panendoscopy
Description: panendoscopy
Study NCT03258216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System
Study NCT02365675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton gauze with petrolatum
Study NCT02365675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellulose acetate with petrolatum
Study NCT02365675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline silver (Acticoat)
Study NCT02365675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose with ionic silver (Aquacel Ag)
Study NCT04227574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise training + WhatsApp anti-inertia reminders
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise.
Study NCT04227574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Time Exercise training alone
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
Study NCT02529150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
Study NCT03965156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1) Ultrasound guided Erector spinae block
Description: In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
Study NCT03965156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
Study NCT00325364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 months
Study NCT00325364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable insulin
Description: patient specific dose, injectable, before meals, 24 months
Study NCT00118716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol
Study NCT00118716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate
Study NCT00661466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00274846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
Study NCT00274846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
Study NCT00274846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Days -5 and -4: 60 mg/kg
Study NCT00274846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Days -5 through -2: 25 mg/m\^2
Study NCT00274846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro treated peripheral blood stem cell transplantation
Description: Day 0 infuse natural killer cells
Study NCT02572999 — intervention group
Intervention type: PROCEDURE
Intervention: Not applicable (observational design)
Study NCT01764152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal sample
Description: The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
Study NCT03630458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet couscous - made in Senegal
Description: Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study NCT03630458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet couscous - made in USA
Description: Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study NCT02787707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persumac
Description: 2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
Study NCT02787707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: 2.7 grams Lactose every 8 hour
Study NCT03630458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet thick porridge
Description: Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study NCT03630458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat couscous
Description: Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study NCT04662281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LX9211 matching-placebo, tablets will be administered orally.
Study NCT04662281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211
Description: LX9211, 200 mg, tablets will be administered orally.
Study NCT04393480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic therapy
Description: ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
Study NCT04393480 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional therapy
Description: Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
Study NCT04393480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
Study NCT01931943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selatinib ditosilate tablets
Study NCT03606928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, oxaliplatin, 5-FU, leucovorin
Description: This is a single-arm study with all patients receiving mFLOT chemotherapy.
Study NCT03055897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux 2020 System
Description: Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
Study NCT01176149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMBG plus intensive education
Study NCT02792192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in respective arm.
Study NCT02792192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin
Description: For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
Study NCT06284057 — intervention group
Intervention type: PROCEDURE
Intervention: Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte
Description: Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.
Study NCT01461317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Participants will receive etrolizumab at a dose of 100 mg.
Study NCT03770039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-06700841 containing 14C microtracer
Description: Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
Study NCT03770039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral unlabeled PF-06700841
Description: 60 mg unlabeled PF-06700841 oral dose in 2nd period
Study NCT03770039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV 14C-labeled PF-06700841
Description: 30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
Study NCT01092091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Arginase I
Description: Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
Study NCT03429933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study NCT03429933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01372488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture self removal
Description: Suture self removal
Study NCT01372488 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suture removal by family doctor or clinic
Description: As above
Study NCT01765348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Syntax treatment via sentence-combining method
Description: Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions.
Study NCT01765348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Syntax treatment managed by narrative-based treatment
Description: Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
Study NCT03550872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
Study NCT00356356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
Study NCT03630458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Description: White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study NCT02967328 — intervention group
Intervention type: OTHER
Intervention: RP% Measurement by FCM as a Diagnostic Test for ITP
Study NCT01867710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
Study NCT01867710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg twice daily
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
Study NCT01867710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg once daily
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
Study NCT01867710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 2.5 mg twice daily
Description: type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
Study NCT01867710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg once daily
Description: type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast